As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

Revenue from collaborative research was $6.8 million for the three months ended September 30, 2024. There was no revenue recognized for the same period in 2023. Revenue for the three months ended ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...